About Ai2 Header

Awarded Bionow ‘North West Biotech Start-up of the Year’ 2005

Received grant funding from UK Government and EU funding bodies amounting to the millions to develop the technology

Secured investment worth £250k from the UMIP Premier Fund, managed by MTI

Four patent families filed to date with several patents granted in key jurisdictions.

Secured £1.75 million joint investment from the North West Fund for Biomedical managers Spark Impact and MTI Firms, managers of the UMIP Premier Fund

Signed first licence deal with Sauflon Pharmaceuticals to apply Ai2 technology to contact lenses and lens care solutions